A 12-week randomized trial found that wholegrain rye did not beat refined wheat for weight loss, but it did reduce inflammation and shift gut microbiota and short-chain fatty acids in potentially beneficial ways.
Key takeaways
Rye did not outperform wheat for weight loss
Rye reduced inflammation after 12 weeks
Rye altered gut bacteria and short-chain fatty acids in potentially beneficial ways
Starting metabolic status may influence response
Study: Effects of hypocaloric wholegrain rye vs refined wheat diets on weight loss, cardiometabolic risk factors and gut microbiota: A 12-week randomized controlled trial. Image Credit: Sham Clicks / Shutterstock
In a recent study published in the journal Clinical Nutrition, researchers in Denmark and Sweden present the outcomes of the RyeWeight2 study. This 12-week randomized controlled trial investigated whether substituting refined wheat with wholegrain rye in a calorie-restricted diet would lead to greater weight loss and improved metabolic health.
Study findings revealed that, while both groups lost significant weight, rye and wheat were statistically indistinguishable in terms of weight-loss efficacy. However, the rye-rich diet was observed to result in significant reductions in biomarkers of systemic inflammation and favorable changes in the gut microbiome. The findings suggest that for individuals with pre-existing insulin resistance, rye may offer additional metabolic effects compared with refined wheat.
Obesity, Whole Grains, and Dietary Interventions
Global health agencies posit overweight and obesity as among the most pressing public health challenges facing today’s society, citing health records that suggest these metabolic conditions and their comorbidities contribute to millions of deaths annually.
Decades of research have aimed to curb excessive weight gain (at the population scale) through dietary interventions. In this context, nutritional science promotes the consumption of whole grains, citing their consistent associations with lower body fat and improved metabolic markers.
Previous research, including the initial RyeWeight1 study, suggested that rye might specifically enhance weight loss by improving appetite control and altering gut-derived metabolites. However, a substantial body of evidence has provided conflicting outcomes, a discrepancy attributed to inter-individual variation and the persistent lack of methodological standardization.
Randomized Controlled Trial Design and Methods
The present study aimed to address the ongoing debate regarding rye’s metabolic benefits by evaluating the whole grain’s impacts on body weight, body composition, metabolic risk markers, and gut bacteria. The study (called “RyeWeight2”) recruited 255 adults with overweight or obesity (BMI = 27-35 kg/m²) for a 12-week parallel intervention. Study participants were randomized in a 1:1 ratio into two groups (rye/experimental versus wheat/control).
Both groups were placed on a hypocaloric diet designed to create a daily energy deficit of 500 kcal. The rye group substituted their habitual grains with wholegrain rye products (providing approximately 30 g of fiber per day), while the other group used refined wheat products (providing only 8 g of fiber).
The study leveraged dual-energy X-ray absorptiometry (DXA) assays to measure participants' changes (from baseline) in body fat and lean mass. Furthermore, shotgun metagenomics and blood biomarker assays were employed to sequence the DNA of participants' gut bacteria and to analyze their blood samples for short-chain fatty acids (SCFAs), metabolic signaling molecules produced when fiber is fermented in the colon, thereby revealing participants’ gut microbial composition.
By the end of the 12-week study, DXA outcomes analyses revealed significant weight loss in both groups. Participants in the rye group lost an average of 3.2 kg (7 lbs), while those in the wheat group lost 2.9 kg (6.4 lbs). However, these differences were not statistically significant (p = 0.32), implying that rye did not outperform wheat in promoting weight loss in the sample cohort.
Inflammation Biomarkers and Gut Microbiome Changes
Notably, blood biomarker assays found that the rye group experienced a 17% reduction in C-reactive protein (CRP; a systemic inflammation marker), whereas the wheat group did not (p = 0.03). Similarly, plasma butyrate (an anti-inflammatory SCFA) was observed to be 38% higher in the rye group by week 12 compared to the wheat group (p = 0.03).
Shotgun metagenomics corroborated these findings by showing that the rye diet was associated with a significant increase in participants’ levels of Bifidobacterium adolescentis, a bacterium previously linked to improved glucose tolerance. Conversely, several microbial taxa linked to negative health outcomes (e.g., Ruminococcus torques) were significantly reduced in the rye consumers compared to their wheat-consuming counterparts.
Insulin Resistance and Individual Response Differences
Unexpectedly, statistical analyses found that participants with higher baseline homeostatic model assessment for insulin resistance (HOMA-IR) levels showed poorer weight loss in the wheat cohort and that baseline HOMA-IR and CRP were associated with weight and fat-mass change, suggesting that the wholegrain diet may be particularly beneficial for individuals with higher baseline insulin resistance and inflammation.
Clinical Implications of Rye Diet Findings
The RyeWeight2 study outcomes indicate that while a wholegrain rye diet may not facilitate improved short-term weight loss compared to a refined wheat-based diet, its effects on gut microbiota and blood biomarkers may have positive implications for cardiometabolic health.
While the RyeWeight2 study failed to replicate the weight-loss findings of the RyeWeight1 study, the authors hypothesized that this discrepancy might be attributed to the current sample being slightly younger than in the first study, and demonstrating improved baseline insulin sensitivity, particularly in the wheat group.
However, the current study suggests that rye has anti-inflammatory effects and can alter the gut microbiome in ways that may have positive implications for cardiometabolic health. The study did not find that baseline gut microbiota predicted weight loss after 12 weeks, nor did it show differences in subjective appetite between the groups.
Future research should aim to investigate these benefits within a "precision nutrition" framework, in which a patient’s baseline inflammation and insulin markers are used to identify the grain that best suits their unique biology.
Activating hypoxia signaling improves metabolism and bone health